Introduction {#sec1}
============

Colorectal cancer is one of the most common malignancies in the Czech Republic; approximately 8,000 new cases of colorectal cancer (of which 4,500 occur in men) are diagnosed annually, and roughly 4,000 patients die from it per year \[[@cit0001]\].

Rectal resection plays a major role in the treatment of rectal cancer. One of the most dreaded complications of rectal surgery is an anastomotic healing complication. Anastomotic leakage (AL) (i.e. leakage of intestinal contents into the surroundings) resulting in pericolic or perirectal abscesses is associated with increased risk of local tumor recurrence and shorter survival, as well as poor functional results \[[@cit0002]--[@cit0005]\]. The incidence of AL has been reported to range from 2.5% to 21% \[[@cit0006]--[@cit0011]\].

The primary risk factors for AL include male gender, obesity, duration of surgery exceeding 270 min, greater blood loss, and preoperative chemo/radiotherapy. Low and ultra-low anterior rectal resection are also significant risk factors \[[@cit0002], [@cit0006]\]. In an effort to enable risk prediction and early diagnosis of AL, numerous scoring systems have been created and a broad spectrum of various laboratory parameters has been evaluated. Unfortunately, apart from C-reactive protein (CRP) and leukocyte count, other indicators have not been found \[[@cit0012]\].

One method of predicting anastomotic healing complications prior to clinical manifestation is monitoring the concentrations of neopterin, tryptophan, and kynurenine in bodily fluids.

According to recent literature, evaluation of elevated neopterin levels has not been used to predict postoperative colorectal carcinoma complications.

Aim {#sec2}
===

This study aimed to evaluate the potential use of neopterin and other biochemical markers (e.g. kynurenine/neopterin and kynurenine/tryptophan ratios) as predictors of complications associated with anastomotic healing after rectal resection for cancer. The basic working hypothesis is an expected significant increase in these markers, or changes in their ratios within bodily fluids (serum, urine, drainage fluid) in patients with anastomotic healing complications.

Material and methods {#sec3}
====================

This prospective clinical study included patients who underwent elective rectal resection with primary anastomosis, constructed using the double-stapling technique, at the Hradec Králové University Hospital Surgical Clinic between 1.11.2014 and 30.11.2015. Patients with manually sewn coloanal anastomoses and patients after palliative procedures (i.e. bypass surgery, derivative stoma or probatory laparotomy) were not included in the study. Patients were selected for the laparoscopic approach based on the patient's overall condition and history of abdominal surgery. Otherwise they underwent an open procedure.

Initial levels of neopterin, tryptophan, kynurenine, and their ratios in serum and urine, were determined from venous blood samples and urine samples taken just prior to surgery. From the 1^st^ to the 6^th^ postoperative day, kynurenine and tryptophan levels, as well as their ratios in serum, urine, and drainage fluid, were monitored until the time of their removal \[[@cit0013], [@cit0014]\]. Also on the 2^nd^ and 5^th^ postoperative days, leukocyte counts and CRP levels in venous blood were assessed. The following additional patient data were analyzed: a) demographic: age, sex, body mass index (BMI), comorbidity index of American Society of Anesthesiologists (ASA) score; b) oncologic: clinical and pathologic tumor staging, tumor grading, tumor invasiveness (presence of angioinvasion, lympho-angioinvasion, perineural invasion), rectal tumor localization; c) therapeutic: completion of neoadjuvant chemoradiotherapy, type of surgical procedure, extent of mesorectal excision, extent of interruption to the arterial supply to the rectum, use of protective ileostomy, procedure radicality; d) clinical: occurrence of AL and its classification \[[@cit0015]\]. Data were prospectively entered into the ProMed database of patients with rectal cancer.

This study was approved by the Ethics Committee, Hradec Králové University Hospital.

Statistical analysis {#sec3.1}
--------------------

Statistical analyses were performed using SPSS Statistics 22.0 software (SPSS Inc., Chicago, IL, USA). *P*-values \< 0.05 were considered statistically significant. The χ^2^ test for independence in a contingency table and Fisher's exact test were used.

Results {#sec4}
=======

A total of 48 patients with rectal cancer, during the previously mentioned period, were enrolled in the study. Two patients were excluded from the study due to having undergone primary treatment with Hartmann's operation, and 4 patients were excluded due to having undergone a manually sewn coloanal anastomosis. Data were analyzed for a total of 42 patients with rectal cancer who underwent a double-stapled rectal anastomosis. Thirty-six patients underwent a laparoscopic resection and 6 patients had an open procedure. No conversion was found in the analyzed group of the patients.

Of the entire sample, 16 (38.1%) patients had various anastomotic healing complications, and 26 (61.9%) patients experienced a postoperative course without serious complications.

Type-A AL, not requiring therapeutic intervention, occurred in 7 of 16 (43.8%) patients. Type-B AL, requiring non-surgical intervention -- most frequently rectal lavage or treatment with an Endo-Sponge (B-Braun Medical BV, Melsungen, Germany) -- occurred in 5 of 16 (31.2%) patients. Type-C AL occurred in 4 of 16 (25.0%) patients, for whom relaparotomy was performed ([Table I](#t0001){ref-type="table"}).

###### 

Analysis of AL per severity

  Anastomotic leak   *N*   \%
  ------------------ ----- -------
  Type A             7     43.8
  Type B             5     31.2
  Type C             4     25.0
  Total              16    100.0

During statistical analyses of AL vs. no complications, no differences in demographic data except age were observed ([Table II](#t0002){ref-type="table"}). The groups were also comparable in terms of oncologic parameters. Likewise, no significant differences in clinical stage, pathologic stage, tumor grade, or even invasiveness (lympho-angioinvasion, perineural invasion), were found. Tumor distribution, according to the location, had borderline statistical significance (*p* = 0.055). Distal rectal cancer was more often seen in the AL group (37.5%) than in the group without complications (11.5%). Conversely, 13 of 26 (50.0%) patients with upper rectal cancer were in the group without complications, while only 3 of 16 (18.8%) were in the AL group ([Tables III](#t0003){ref-type="table"} and [IV](#t0004){ref-type="table"}). Postoperative course was not influenced by the type of surgery (open/laparoscopic), protective stoma construction, or even procedure radicality. Conversely, results were statistically different regarding mesorectal excisions, *p* = 0.015. The total mesorectal excision (TME) was used in 93.7% (15 patients) in the AL group, and 57.7% (15 patients) in the group without complications. Not even the extent of arterial interruption influenced AL in the sample (*p* = 0.465) ([Table IV](#t0004){ref-type="table"}).

###### 

Patient demographic data

  Parameter                     Without AL   AL      *P*-value            
  ----------------------------- ------------ ------- ------------ ------- -------
  Sex:                                                                    0.421
   Male                         15           57.7    12           75.0    
   Female                       11           42.3    4            25.0    
  Age:                                                                    0.013
   Mean                         62.2                 68.1                 
   Median                       63.5                 67                   
   Range                        44--75               58--81               
  BMI:                                                                    0.341
   Mean                         27.8                 27.4                 
   Median                       27.8                 27.2                 
   Range                        21.3--34.6           22.4--31.9           
  ASA:                                                                    0.138
   1                            1            3.8     0            0       
   2                            19           73.1    9            56.3    
   3                            6            23.1    7            43.7    
   4                            0            0       0            0       
  Diabetes mellitus:                                                      0.628
   Positive                     2            7.7     2            12.5    
    Negative                    24           92.3    14           87.5    
  Cardiovascular comorbidity:                                             0.940
   Positive                     13           50.0    9            56.3    
   Negative                     13           50.0    7            43.7    
  Pulmonary disease:                                                      1.000
   Positive                     1            3.8     0            0       
   Negative                     25           96.2    16           100.0   
  Corticoids:                                                             N/A
   Positive                     0            0       0            0       
   Negative                     25           100.0   16           100.0   

N/A -- not applicable/not available.

###### 

Data associated with tumors

  Parameter                    Without AL   AL     *P*-value          
  ---------------------------- ------------ ------ ----------- ------ -------
  Clinical stage:                                                     0.454
   I                           8            30.8   2           12.5   
   II                          2            7.7    3           18.8   
   III                         16           61.5   11          68.7   
   IV                          0            0      0           0      
  Pathologic stage                                                    0.298
  Complete response:           4            15.4   1           6.3    
   I                           13           50.0   7           43.7   
   II                          3            11.5   2           12.5   
   III                         6            23.1   6           37.5   
   IV                          0            0      0           0      
  Grade:                                                              0.066
   Well-differentiated         7            26.9   0           0      
   Moderately differentiated   19           73.1   15          93.7   
   Poorly differentiated       0            0      1           6.3    
  Angioinvasion:                                                      0.352
   Positive                    2            7.7    3           18.8   
   Negative                    24           92.3   13          81.2   
  Lympho-angioinvasive:                                               1.000
   Positive                    3            11.5   2           12.5   
    Negative                   23           88.5   14          87.5   
  Perineural invasion:                                                0.352
   Positive                    2            7.7    3           18.8   
   Negative                    24           92.3   13          81.2   

###### 

Data associated with treatment

  Parameter                        Without AL   AL     *P*-value          
  -------------------------------- ------------ ------ ----------- ------ -------
  Neoadjuvant therapy:                                                    0.988
   w/o neoadjuvant therapy         12           46.2   6           37.5   
   Chemoradiotherapy               14           53.8   10          62.5   
  Tumor localization:                                                     0.055
   Upper rectum                    13           50.0   3           18.8   
   Middle rectum                   10           38.5   7           43.7   
   Lower rectum                    3            11.5   6           37.5   
  Type of procedure:                                                      0.658
   Open                            3            11.5   3           18.8   
   Laparoscopic                    23           88.5   13          81.2   
  Derivative stoma:                                                       1.000
   Positive                        7            26.9   4           25.0   
   Negative                        19           73.1   12          75.0   
  Radicality:                                                             1.000
   R0                              25           96.2   15          93.7   
   R1                              1            3.8    1           6.3    
   R2                              0                   0                  
  Extent of mesorectal excision:                                          0.015
   Total                           15           57.7   15          93.7   
   Partial                         11           42.3   1           6.3    
  Dissected vessel:                                                       0.465
   Superior rectal artery          21           80.8   11          68.8   
   Inferior mesenteric artery      5            19.2   5           31.2   

The leukocyte count in the group without complications was 8.4 × 10^4^ and in the AL group was 9.8 × 10^4^ on the 2^nd^ postoperative day (*p* = 0.047). The leukocyte count in the group without complications was 6.3 × 10^4^, and in the AL group was 8.6 × 10^4^ on the 5^th^ postoperative day (*p* = 0.010) ([Table V](#t0005){ref-type="table"}).

###### 

Leukocyte count

  Day     Mean leukocyte count (1 × 104)   *P*-value   
  ------- -------------------------------- ----------- -------
  2^nd^   8.4                              9.8         0.047
  5^th^   6.3                              8.6         0.010

The differences in CRP levels between the groups were more pronounced. On the 2^nd^ postoperative day, the CRP values were 79.1 mg/l in the group without complications, and 142.4 mg/l in the AL group (*p* = 0.002). An even more significant difference was observed on the 5^th^ postoperative day, when the group without complications had a CRP level of 31.8 mg/l, and the AL group had a CRP level of 151.9 mg/l (*p* \< 0.001) ([Table VI](#t0006){ref-type="table"}).

###### 

C-reactive protein (CRP) levels

  Day     Mean CRP level \[mg/l\]   *P*-value   
  ------- ------------------------- ----------- ----------
  2^nd^   79.1                      142.4       0.002
  5^th^   31.8                      151.9       \< 0.001

No statistically significant differences were found among neopterin, tryptophan, and serum kynurenine levels ([Table VII](#t0007){ref-type="table"}).

###### 

Results for neopterin and kynurenine in sera

  ----------------------------------------------------------------------------------------
  Parameter                             Without AL   With AL   *P*-value           
  ------------------------------------- ------------ --------- ----------- ------- -------
  Neopterin \[nmol/l\]                  9.36         2.52      18.08       8.83    0.118

  Kynurenine initial \[μmol/l\]         3.96         7.09      2.65        1.38    0.820

  Kynurenine \[μmol/l\]                 2.19         0.43      2.50        0.81    0.108

  Kynurenine/tryptophan initial\        115.38       236.96    59.80       42.93   0.888
  \[μmol/mmol\]                                                                    

  Kynurenine/tryptophan \[μmol/mmol\]   51.80        16.27     59.55       18.70   0.089
  ----------------------------------------------------------------------------------------

On the other hand, the urinary neopterin/creatinine (NEO/CREA) ratio was very promising. Prior to surgery, this parameter had a significant statistical difference (*p* = 0.037). The mean NEO/CREA ratio was 139.5 μmol/mol in those who would go on to have AL, and 114.8 μmol/mol in those who would go on to have no complications. An even greater statistically significant difference was seen in the average NEO/CREA ratio for the entire observation period; 185.1 μmol/mol in AL patients vs. 142.8 μmol/mol in patients without complications (*p* = 0.012) ([Table VIII](#t0008){ref-type="table"}).

###### 

Results for urinary neopterin

  Parameter                                   Without AL   AL        *P*-value             
  ------------------------------------------- ------------ --------- ----------- --------- -------
  Neopterin initial \[nmol/l\]                2526.21      1268.85   4125.06     4540.81   0.128
  Neopterin \[nmol/l\]                        2583.88      1700.87   3655.53     3083.19   0.129
  Neopterin/creatinine initial \[μmol/mol\]   114.73       35.54     139.47      44.28     0.037
  Neopterin/creatinine \[μmol/mol\]           142.75       52.91     185.10      57.96     0.012

A significant difference in neopterin levels was found when monitoring the parameters within the drain (*p* = 0.048); this value was 49.03 nmol/l in the AL group, and 27.89 nmol/l in the group without complications. Another parameter that reached borderline statistical significance (*p* = 0.062) was the neopterin/tryptophan (NEO/TRYP) ratio, which was 0.41 nmol/μmol in patients without complications, and 0.58 nmol/μmol in those with AL ([Table IX](#t0009){ref-type="table"}).

###### 

Results for neopterin, tryptophan, and kynurenine; and their average levels in drainage fluids

  Parameter                             Without AL   AL      *P*-value           
  ------------------------------------- ------------ ------- ----------- ------- -------
  Neopterin \[nmol/l\]                  27.89        11.31   49.03       37.41   0.048
  Tryptophan \[μmol/l\]                 71.25        21.82   76.66       29.58   0.267
  Kynurenine \[μmol/l\]                 2.85         1.34    3.40        1.74    0.282
  Kynurenine/tryptophan \[μmol/mmol\]   53.48        22.58   55.18       18.37   0.448
  Neopterin/tryptophan \[nmol/μmol\]    0.41         0.18    0.58        0.34    0.062

Further statistical analyses found a collective probability of 95% that the pathologic markers were determinative for predicting the risk of AL. The urinary NEO/CREA ratio was 126.64 μmol/mol prior to the procedure vs. 159.16 μmol/mol after the procedure. Neopterin levels in drainage fluid \> 31.53 nmol/l, and NEO/TRYP ratios in drainage fluid \> 0.47 nmol/μmol, were considered pathological.

Discussion {#sec5}
==========

In our study, rectal anastomotic leakage was diagnosed in 16 of 42 patients (38.1%), which is greater than the 2 to 20% range reported in the literature. This is most likely due to careful monitoring of anastomotic healing at our facility, which stems from rectal anastomotic healing surveillance during 3 time periods: i) prior to the end of surgery; ii) 1 week after surgery, prior to hospital discharge; and iii) 4 weeks after surgery. In this way, we can explain the higher incidence of AL and, in particular, greater detection of clinically silent leaks (type A). For example, a recent publication by Japanese authors reported that their patients had a type A AL frequency of only 12%, a type B frequency of 52%, and a type C frequency of 36% \[[@cit0016]\].

Comparison of the group without a complicated course vs. the AL group showed that the 2 samples had statistically significant differences only with regard to the mesorectal excisions (*p* = 0.015). Anastomosis at a distance of \< 5 cm from the anus (thus, performed with TME) is a significant risk factor for the occurrence of AL. This is primarily due to extensive dissection in the distal third of the rectum with potential mechanical and thermal damage to its walls, and disruption of the microcirculation. No other statistically significant differences were found between the groups. This shows that, within the presented sample, neither tumor staging nor neoadjuvant therapy (both denoted in the literature as risk factors) influenced AL occurrence.

Activation of the cellular immune response with activation of the monocyte-macrophage system due to bacterial and viral infections, malignant tumors, autoimmune diseases, or antitumor treatment leads to increased neopterin production \[[@cit0002], [@cit0017]--[@cit0021]\]. Afterward, inflammatory response activity can then be monitored via neopterin levels in various bodily fluids. Our study analyzed these levels in serum, urine, and drainage fluid.

It has been shown that higher neopterin levels are present in patients with septic shock than in patients with noninfectious systemic inflammatory response syndrome (SIRS), which reflects inflammatory response activity \[[@cit0022], [@cit0023]\]. The same results were observed by Ploder *et al.*, during a study in which patients with sepsis or severe trauma had elevated neopterin levels compared to the control group \[[@cit0024]\].

Baydar monitored differences in urinary neopterin levels in a group of patients with SIRS, sepsis, septic shock, and multiple organ dysfunction syndrome (MODS) and compared them to a control group. The mean neopterin level in the control group was 111 ±11 μmol/mol, and 3851 ±1081 μmol/mol in the patient group, *p \<* 0.05. When comparing neopterin levels between individual patient groups, the mean neopterin concentrations were significantly higher in patients with sepsis and septic shock than in those with SIRS \[[@cit0025]\].

A recent study from the same facility that monitored serum neopterin levels showed that neopterin levels were significantly elevated in patients with sepsis, septic shock, and MODS; and these levels simultaneously correlated with the value of acute physiology and chronic health enquiry (APACHE II) scores. Conversely, the group of survivors had lower serum neopterin levels \[[@cit0026]\]. In addition to being an inflammatory response marker, neopterin also serves as a significant prognostic factor for sepsis \[[@cit0027]\].

Our analysis showed that the urinary NEO/CREA ratio prior to the commencement of surgery was significantly higher (*p* = 0.037) in those would go on to be in the AL group vs. those who would recover without complications. In the future, this fact could be used as a major predictor for a high probability of AL and would enable modification of surgical procedures. At-risk patients could undergo protective ileostomy or, in patients with other associated risks (age, sex, radiotherapy, bulky tumors of the distal rectum, distant metastasis), Hartmann's operation is also an option, since it is an effective and safe procedure without a primary anastomosis.

Other statistically significant differences found during the postoperative period included the urinary NEO/CREA ratio (*p* = 0.012), and neopterin levels in drainage fluid from the abdominal drain (*p* = 0.048). The NEO/TRYP ratio in abdominal drainage fluid was borderline statistically significant (*p* = 0.062). These results could, perhaps, be used for the basis of early diagnostics for AL (e.g. colonoscopy, CT imaging) as well as timely and effective therapeutic intervention prior to clinical manifestation. Early intervention can protect anastomoses from complications. In type C AL, for example, it would allow for earlier revision of the abdominal cavity with lavage and pelvic drainage, possibly even a protective ileostomy. In type B AL, it would allow for earlier application of local procedures to stop AL and serve as a basis for antibiotic therapy.

On the other hand, our study failed to find any value in monitoring tryptophan, kynurenine, and their ratios. Nonetheless, the results of an Austrian study, which compared tryptophan levels and the kynurenine/tryptophan (KYN/TRYP) ratio in polytrauma patients, showed that tryptophan concentrations decreased in all trauma patients compared to the control group (which had increased KYN/TRYP ratios and kynurenine concentrations) \[[@cit0024]\]. This is also in line with results from a study by Girgin *et al.*, which showed that the KYN/TRYP ratio unambiguously correlated with sepsis severity \[[@cit0026]\].

In line with other research \[[@cit0028], [@cit0029]\], our study demonstrated that CRP levels \> 140 mg/l indicate a pathological postoperative course. On the 2^nd^ postoperative day, this value was borderline; but it was unambiguous on the 5^th^ postoperative day. In our sample, there were statistically significant differences in CRP levels between the groups ([Table V](#t0005){ref-type="table"}). Pedersen *et al.* demonstrated that postoperative CRP levels were significantly elevated in patients with septic complications, and lower in patients with an uncomplicated course. The best cut-off value for CRP as a predictor of septic complications was on the 3^rd^ postoperative day, when CRP levels were \> 200 mg/l. This assessment method had a sensitivity of 68% and a specificity of 74%. The best cut-off value for leukocyte count was on the 2^nd^ postoperative day, with a value \> 12 × 10^4^, a sensitivity of 90%, and a specificity of 62% \[[@cit0030]\].

Unfortunately, CRP levels (as with other methods based on monitoring blood markers induced by activation of the monocyte-macrophage system) are unable to distinguish AL sepsis from other causes. The AL is the most frequent cause of septic complications after rectal resection with primary anastomosis and it is, therefore, necessary to actively look for this complication when elevated CRP levels are seen.

Conclusions {#sec6}
===========

Our study has shown that high urinary neopterin levels prior to surgical treatment can be interpreted as a useful biochemical predictor of AL. It makes it relatively easy to identify patients at high risk for AL and modify surgical tactics in terms of the absolute indication for a protective ileostomy to prevent severe septic complications associated with AL or, in patients with other known risks for primary rectal anastomosis, complete the procedure with Hartmann's operation with a definitive terminal colostomy. At the same, pathological levels of neopterin in urine and abdominal drainage during the postoperative period can be used as an indicator of AL.
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